Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > Bing on the study:
View:
Post by prophetoffactz on Feb 02, 2024 10:33am

Bing on the study:

The 1% avenanthramide treatment described in the study appears to have intriguing effects on tissue healing. Let’s explore its potential applications:

  1. Wound Healing and Skin Repair:

    • The promotion of an extracellular matrix (ECM) architecture similar to unwounded skin suggests that this treatment could be beneficial for wound healing and tissue repair.
    • The presence of shorter, more randomly aligned collagen fibers is associated with improved wound healing.
    • Reduced inflammatory cell presence indicates a potential anti-inflammatory effect, which is crucial for healing.
  2. Dermatological Conditions:

    • Given its positive impact on ECM architecture and collagen fibers, this treatment might be useful for managing skin conditions such as scarringburns, or chronic wounds.
    • It could potentially enhance the healing process in conditions like eczemapsoriasis, or dermatitis.
  3. Orthopedics and Bone Healing:

    • While the study focused on skin tissue, the concept of promoting ECM architecture and reducing inflammation could extend to other tissues.
    • Considering the role of collagen in bone health, this treatment might have implications for bone healing, especially in cases of fractures or bone-related injuries.
  4. Cardiovascular Health:

    • Although not directly studied for atherosclerosis, the positive effects on ECM and inflammation reduction raise interesting possibilities.
    • Atherosclerosis involves changes in blood vessel walls, and promoting a healthy ECM could potentially benefit vascular health.
    • Further research would be needed to explore this application.
  5. Anti-Inflammatory Therapies:

    • The reduction in inflammatory cell presence suggests an anti-inflammatory effect.
    • This could be relevant for conditions beyond wound healing, such as arthritisinflammatory skin disorders, or even systemic inflammation.
  6. Cosmetic and Anti-Aging Products:

    • The impact on collagen fibers aligns with the goals of many cosmetic products.
    • Avenanthramides might find applications in anti-aging creamsskin rejuvenation, or collagen-enhancing formulations.

Remember that while these potential applications are intriguing, further research and clinical trials are necessary to validate the effectiveness and safety of avenanthramide treatments. Always consult with healthcare professionals before considering any new therapies or treatments.

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities